Peginesatide (Omontys) for anemia in chronic kidney disease

Medical Letter on Drugs and Therapeutics

Volumn 54, Issue 1392, 2012, Pages 45-46

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; PEPTIDE;

ANEMIA; ARTHRALGIA; BACKACHE; CHRONIC KIDNEY DISEASE; COUGHING; DIALYSIS; DIARRHEA; DRUG COST; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; LEG PAIN; LETTER; MUSCLE SPASM; NAUSEA; SEIZURE; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; UNITED STATES;

ANEMIA; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; PEPTIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865083592     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. D Cotter et al. Translating epoetin research into practice: the role of government and the use of scientific evidence. Health Aff 2006; 25:1249.
2. Erythropoietin safety concerns. Med Lett Drugs Ther 2007; 49:37.
3. B Schiller et al. Safety and efficacy of peginesatide for treatment of anemia in hemodialysis patients previously on epoetin alfa (EMERALD 1). National Kidney Foundation 2011 Spring Clinical Meeting; April 26-30, 2011; Las Vegas, NV.
4. A Besarab et al. Safety and efficacy of peginesatide for treatment of anemia in hemodialysis patients previously on epoetin alfa or beta (EMERALD 2). National Kidney Foundation 2011 Spring Clinical Meeting; April 26-30, 2011; Las Vegas, NV.